Havana, Feb 25.- Thousands of doses of the Cuban Covid-19 vaccines are produced today in Cuban laboratories.
The Center for Genetic Engineering and Biotechnology (CIGB), leader of the vaccine candidate Abdala, joins this productive escalation.
The idea, as with Soberana 02, is to provide enough doses to continue this next stage of the clinical trial with more volunteers to verify its efficiency, and then expand it to the rest of the population.
According to its developers, Abdala demonstrated safety and immunogenicity against Covid-19 in phase II, while two months before phase I began, the scientists favorably verified its safety and reactogenicity profile.
The biopharmaceutical industry, for its part, already produces the molecule on a large scale and to achieve it, several scientific institutions combine knowledge and experience in the production of drugs with good practices.
In the case of Abdala, the Aica laboratories, of the BioCubaFarma business group, are in charge of production.
Its executives previously explained that the industry has sufficient installed capacity, with technology to produce more than 100,000 bulbs per day, with filling volumes of 12,000 per hour.
Soberana 02 and Abdala are not the only anti-Covid-19 formulations carried out by the Cuban scientific community.
They are investigating two other molecules, Sovereign 01 (IFV) and Mambisa (CIGB), the latter the only one designed by nasal route.
The idea is to work on various formulations to benefit people of different ages and have the possibility of vaccinating the entire population, according to specialists.
Cuba could have a large part of its population immunized in 2021. (Text and photo: PL)